星点设计-响应面法优化氯诺昔康纳米结构脂质载体处方

发布时间：2018-04-18 01:01

  本文选题：星点设计-响应面法 + 氯诺昔康　； 参考：《中国药房》2017年28期

【摘要】：目的:优化氯诺昔康纳米结构脂质载体(LN-NLC)处方。方法:采用乳化-溶剂挥发法制备LN-NLC,以药脂比、大豆磷脂用量、液脂比(液态脂质占总脂质比例)、乳化剂用量为因素,以粒径、Zeta电位、包封率为指标计算总评归一值作为综合指标,通过星点设计-响应面法优化处方,并考察所制LN-NLC的外观形态和稳定性。结果:最优处方为药脂比1∶50,大豆磷脂用量162.5mg,液脂比25%,乳化剂用量958.2 mg。所制LN-NLC的粒径为(96.9±3.3)nm、Zeta电位为(-16.1±0.3)mV、包封率为(60.1±0.9)%(n=3),与预测值的相对误差分别为2.47%、-4.55%、-0.17%;LN-NLC呈圆球形,4℃下密封保存30 d后粒径和Zeta电位无明显变化,包封率仅降低了1.2%。结论:成功优化LN-NLC处方,所制LN-NLC稳定性良好。
[Abstract]:Objective: to optimize the formulation of lornoxicam nanostructured lipid carrier LN-NLC.Methods: LN-NLCs were prepared by emulsification-solvent volatilization method. The ratio of lipids to total lipids, the ratio of liquid lipids to total lipids, and the amount of emulsifier were used to prepare LN-NLCs with the particle size of Zeta potential.The encapsulation efficiency is used as the index to calculate the general evaluation value as the comprehensive index, the formulation is optimized by the star-point design-response surface method, and the appearance and stability of the LN-NLC are investigated.Results: the optimum prescription was as follows: ratio of lipids to lipids 1: 50, dosage of soybean phospholipids 162.5 mg, ratio of liquid to lipid 25 and emulsifier 958.2 mg.The particle size of LN-NLC was 96.9 卤3.3nmGV and the entrapment efficiency was 60.1 卤0.90.The relative error with the predicted value was 2.47- 4.55- 0.17NLC, and the particle size and Zeta potential did not change significantly after 30 days of storage at 4 鈩，

本文编号：1766070